Loading data for RAPP — first visit, this takes a few seconds.
Rapport Therapeutics, Inc. (RAPP)
NasdaqGM: RAPP
· 实时价格 · USD
46.31
+0.54 (1.18%)
收盘价： Sep 09, 2026, 8:00 PM
44.00
+0.26%
盘前: 9:13 AM
股价、关键数字和最新消息，都在这一页。
Rapport Therapeutics, Inc.（RAPP）股价、分析与数据
暂无数据
| 买价 | 30.56 |
| 市值 | 2.11B |
| 营收（TTM） | 20M |
| 净利润（TTM） | -137M |
| 1.03 | |
| -2.89 | |
| n/a | |
| -8.39 | |
| 市净率（TTM） | 4.98 |
| 市销率（TTM） | 105.28 |
| 财报日期 | Nov 5, 2026 |
| 卖价 | 52.54 |
| 成交量 | 158,063 |
| 20日均量 | 358,796 |
| 开盘价 | 45.01 |
| 前收盘价 | 45.77 |
| 日内区间 | 44.67 - 47.00 |
| 52周区间 | 22.06 - 52.93 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 RAPP
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment ...
公司完整简介财报意外
Rapport Therapeutics 已于 Aug 5, 2026 发布季度财报：
- 营收为 $0 低于预期 $0, ， NaN% 同比增长.
- 每股收益为 -1.19 低于预期 -0.20, ， -58.67% 同比下滑.
第 1 页，共 2 页